Patient-reported atopic dermatitis (AD) severity appears to be sufficiently valid for assessing AD severity in the clinical and epidemiological setting, according to a recent study. Researchers performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n=265). They found:
- At baseline and follow-up, patient-reported global AD severity significantly correlated with objective Scoring Atopic Dermatitis (oSCORAD, Spearman rho=0.56 and 0.49), SCORAD (0.64 and 0.56), Eczema Area Severity Index (EASI, 0.56 and 0.50), Body Surface Area (BSA, 0.52 and 0.45), Itch Numeric Rating Scale (NRS-itch, 0.60 and 0.53), Patient Oriented Eczema Measure (POEM, 0.50 and 0.48), and Dermatology Life Quality Index (DLQI, 0.50 and 0.49).
- Patient-reported moderate and severe AD vs mild AD were associated with significantly higher oSCORAD, SCORAD, EASI, BSA, NRS-itch, POEM, and DLQI.
- There was moderate concordance between patient-reported AD severity (mild, moderate, and severe) and previously developed severity strata for oSCORAD (kappa=0.39), SCORAD (kappa=0.47), EASI (kappa=0.37), NRS-itch (kappa=0.49), POEM (kappa=0.37), and DLQI (kappa=0.40).
Vakharia PP, Chopra R, Sacotte, et al. Validation of patient-reported global severity of atopic dermatitis in adults. [Published online ahead of print September 14, 2017]. Allergy. doi:10.1111/all.13309.